690264-39-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-(trifluoromethoxy)phenol is used as a key intermediate in the synthesis of numerous pharmaceutical drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic applications in various medical fields.
Used in Organic Synthesis:
In the field of organic synthesis, 4-bromo-2-(trifluoromethoxy)phenol serves as a versatile building block for the creation of a wide range of organic compounds. Its reactivity and functional groups make it suitable for various chemical reactions, leading to the formation of new molecules with diverse applications.
Used in Chemical Research:
4-Bromo-2-(trifluoromethoxy)phenol is also utilized in chemical research as a model compound to study the effects of bromine and trifluoromethoxy substitutions on the properties and reactivity of phenol rings. This research can provide valuable insights into the design and synthesis of new molecules with specific characteristics and applications.

InChI:InChI=1/C7H4BrF3O2/c8-4-1-2-5(12)6(3-4)13-7(9,10)11/h1-3,12H

Upstream product

• 32858-93-8 2-(trifluoromethoxy)phenol 

Downstream Products

• 845655-33-6 (2S)-2-(4-Bromo-2-trifluoromethoxy-phenoxy)-propionic acid methyl ester 
• 902757-20-4 4-bromo-1-isopropoxy-2-trifluoromethoxybenzene 
• 690264-40-5 1-[2-(4-bromo-2-trifluoromethoxy-phenoxy)-ethyl]-pyrrolidine 
• 647856-30-2 1-(benzyloxy)-4-bromo-2-(trifluoromethoxy)benzene 
• 1174657-93-2 1-(4-benzyloxy-3-trifluoromethoxyphenyl)-2-bromoethanone 
• 1174657-94-3 2-(4-(benzyloxy)-3-(trifluoromethoxy)phenyl)-2-oxoethyl 4-(tert-butoxycarbonylamino)butanoate 
• 1174657-95-4 2-(4-hydroxy-3-(trifluoromethoxy)phenyl)-2-oxoethyl 4-(tert-butoxycarbonylamino)butanoate 
• 1174657-96-5 4-(2-(4-hydroxy-3-trifluoromethoxyphenyl)-2-oxoethoxy)-4-oxobutan-1-amine trifluoroacetate 
• 1042703-39-8 C₉H₇F₃O₄ 
• 1174657-92-1 1-(4-(benzyloxy)-3-(trifluoromethoxy)phenyl)ethanone 
• 1254062-76-4 4-bromo-1-(cyclopropylmethoxy)-2-(trifluoromethoxy)benzene 
• 1253969-87-7 4-bromo-2-chloro-6-(trifluoromethoxy)phenol 
• 1095544-47-0 4-bromo-1-ethoxy-2-(trifluoromethoxy)benzene 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

P-Hydroxyphenacyl photoremovable protecting groups Robust photochemistry despite substituent diversity

A broadly based investigation of the effects of a diverse array of substituents on the photochemical rearrangement of p-hydroxyphenacyl esters has demonstrated that common substituents such as F, MeO, CN, CO2R, CONH2, and CH3 have little effect on the rate and quantum efficiencies for the photo-Favorskii rearrangement and the release of the acid leaving group or on the lifetimes of the reactive triplet state. A decrease in the quantum yields across all substituents was observed for the release and rearrangement when the photolyses were carried out in buffered aqueous media at pHs that exceeded the ground-state pKa of the chromophore where the conjugate base is the predominant form. Otherwise, substituents have only a very modest effect on the photoreaction of these robust chromophores.

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), Wherein X1 , R1 , R2 , R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

INDOLES USEFUL IN THE TREATMENT OF INFLAMATION

There is provided compounds of formula (I), Wherein T, Y, X1 , R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

Piperazine derivatives

This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1 to R5 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives. The compounds of the present invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, or AIDS.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY

Novel N-hydroxyamide derivatives are disclosed. These N-hydroxyamide derivatives inhibit UPD-3O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria and are therefore useful as antimicrobials and antibiotics. Methods of synthesis and of use of the compounds are also disclosed.